Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common-Size Income Statement

Biogen Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Product, net 80.56 79.53 79.15 80.93 84.36
Revenues from anti-CD20 therapeutic programs 15.10 14.71 15.93 14.72 12.70
Other 4.34 5.76 4.92 4.36 2.93
Revenue 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of sales, excluding amortization and impairment of acquired intangible assets -19.21 -13.43 -13.60 -13.50 -13.28
Gross profit 80.79% 86.57% 86.40% 86.50% 86.72%
Research and development -22.78 -29.68 -15.86 -19.31 -18.36
Selling, general and administrative -24.35 -18.63 -16.52 -15.66 -15.77
Amortization and impairment of acquired intangible assets -8.03 -3.46 -3.41 -5.55 -6.64
Collaboration profit sharing -0.07 -1.73 -1.68 -1.38 -0.91
Gain (loss) on divestiture of Hillerød, Denmark manufacturing operations 0.00 0.69 -0.38 0.00 0.00
Gain (loss) on fair value remeasurement of contingent consideration 0.46 0.64 0.44 0.09 -0.51
Acquired in-process research and development -0.16 -0.56 0.00 -0.84 -0.98
Restructuring charges 0.00 0.00 -0.01 -0.09 -0.01
Income from operations 25.87% 33.84% 48.98% 43.77% 43.54%
Interest income 0.10 0.31 0.83 0.84 0.64
Interest expense -2.31 -1.65 -1.30 -1.49 -2.04
Gain (loss) on investments, net -7.51 5.10 1.42 0.89 -0.30
Foreign exchange gains (losses), net -0.20 -0.08 -0.05 -0.07 0.05
Other, net -0.05 0.02 -0.33 -0.08 -0.11
Other income (expense), net -9.98% 3.70% 0.58% 0.08% -1.75%
Income before equity in income (loss) of investee and income tax expense 15.89% 37.54% 49.56% 43.85% 41.79%
Equity in income (loss) of investee, net of tax 0.32 0.04 -0.55 0.00 0.00
Income before income tax expense 16.21% 37.58% 49.01% 43.85% 41.79%
Income tax expense -0.48 -7.38 -8.05 -10.60 -20.03
Net income 15.73% 30.20% 40.96% 33.26% 21.75%
Net income attributable to noncontrolling interests, net of tax -1.56 -0.45 0.00 -0.32 -1.07
Net income attributable to Biogen Inc. 14.17% 29.76% 40.96% 32.93% 20.69%

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc. income from operations as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.
Income before income tax expense Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc. income before income tax expense as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc. net income attributable to Biogen Inc. as a percentage of revenue decreased from 2019 to 2020 and from 2020 to 2021.